{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:36:50Z","timestamp":1747208210030,"version":"3.40.5"},"reference-count":17,"publisher":"Informa UK Limited","issue":"18","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.2217\/imt-2021-0130","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T08:17:01Z","timestamp":1634199421000},"page":"1549-1554","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Use of Upadacitinib in the Treatment of Psoriatic Arthritis"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-8960","authenticated-orcid":false,"given":"Yael","family":"Ross","sequence":"first","affiliation":[{"name":"Case Western University at MetroHealth Medical Center, Cleveland, OH\u00a0; 44109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-5619","authenticated-orcid":false,"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Division Chief, University Hospital\rCleveland, OH\u00a044106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000711"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2018.345"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214776"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4428"},{"issue":"10","key":"e_1_3_2_10_1","first-page":"Abstract 1350","article-title":"Safety profile of upadacitinib in psoriatic arthritis: integrated analysis from two Phase III trials","volume":"72","author":"Burmester G","year":"2020","unstructured":"Burmester G , WinthropK , NashPet al. Safety profile of upadacitinib in psoriatic arthritis: integrated analysis from two Phase III trials. Arthritis Rheumatol.72(Suppl. 10), Abstract 1350 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00305-z"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00209-4"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key070"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1856"},{"key":"e_1_3_2_19_1","unstructured":"Pfizer Inc. Pfizer shares co-primary endpoint results from post-marketing required safety study of xeljanz \u00ae (tofacitinib) in subjects with rheumatoid arthritis (RA) (2021). https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2021-0130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:10:17Z","timestamp":1715958617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2021-0130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":17,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.2217\/imt-2021-0130"],"URL":"https:\/\/doi.org\/10.2217\/imt-2021-0130","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"type":"print","value":"1750-743X"},{"type":"electronic","value":"1750-7448"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}